Esperion Therapeutics (NASDAQ:ESPR) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04, Zacks reports. The business had revenue of $69.11 million for the quarter, compared to analyst estimates of $61.58 million.

Esperion Therapeutics Price Performance

NASDAQ:ESPR traded up $0.10 during trading hours on Friday, reaching $1.69. 3,260,581 shares of the company traded hands, compared to its average volume of 4,053,618. Esperion Therapeutics has a 1-year low of $1.56 and a 1-year high of $3.94. The stock has a market cap of $332.99 million, a P/E ratio of -2.64 and a beta of 1.01. The firm's 50-day moving average is $1.97 and its 200-day moving average is $2.08.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ESPR. StockNews.com cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, JMP Securities reissued a "market outperform" rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $6.75.

Remove Ads

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.